Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-17
2000-10-10
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544291, C07D40714, A61K 31517
Patent
active
06130218&
ABSTRACT:
A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 15.40.degree., 16.85.degree., 18.06.degree., 24.15.degree. and 25.81.degree.. Owing to its crystalline properties, the new form of doxazosin mesylate according to the invention has surprising advantages both with regard to its synthesis and for pharmaceutical processing into solid dosage forms. A process for preparing the new form of doxazosin mesylate and pharmaceutical compositions comprising the new form of doxazosin mesylate are also described.
REFERENCES:
patent: 2699054 (1955-01-01), Conover
patent: 4092315 (1978-05-01), Bianco
patent: 4188390 (1980-02-01), Campbell
patent: 4251532 (1981-02-01), Roteman
patent: 4816455 (1989-03-01), Schickaneder et al.
patent: 5294615 (1994-03-01), Meyer et al.
patent: 5412095 (1995-05-01), Morley et al.
patent: 5504207 (1996-04-01), Mannino et al.
Grcman et al, Farm. vestn., 48, p. 292 (1997).
Xu Liying et al, Chinese Journal of Medicinal Chemistry, vol. 5, No. 4, p. 266 (1995).
The Merck Index, eleventh edition, Merck & Co., Inc., Rahway, New Jersey, p. 539 (1989).
USAN and the USP Dictionary of Drug Names, Mack Printing Company, Easton, Pennsylvania, p. 197 (1998).
The Merck Index, 1996, Merck & Co., Inc. Whitehouse Station, N.J., XP002030968, #3489: Doxazosin.
Grcman et al., Chemical Abstracts, vol. 128, entry 7263 (1997).
Grafe Ingomar
Morsdorf Johann Peter
Ford John M.
Heumann Pharma GmbH
LandOfFree
Polymorphic form of doxazosin mesylate (Form I) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphic form of doxazosin mesylate (Form I), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic form of doxazosin mesylate (Form I) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257135